Maravai LifeSciences Holdings Inc (MRVI) concluded trading on Wednesday at a closing price of $2.43, with 5.28 million shares of worth about $12.83 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.41% during that period and on Wednesday the price saw a loss of about -5.81%. Currently the company’s common shares owned by public are about 141.59M shares, out of which, 117.88M shares are available for trading.
Stock saw a price change of -6.90% in past 5 days and over the past one month there was a price change of -40.73%. Year-to-date (YTD), MRVI shares are showing a performance of -55.41% which decreased to -68.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.37 but also hit the highest price of $11.56 during that period. The average intraday trading volume for Maravai LifeSciences Holdings Inc shares is 2.86 million. The stock is currently trading -18.54% below its 20-day simple moving average (SMA20), while that difference is down -41.42% for SMA50 and it goes to -63.69% lower than SMA200.
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) currently have 141.59M outstanding shares and institutions hold larger chunk of about 86.81% of that.
The stock has a current market capitalization of $613.64M and its 3Y-monthly beta is at 0.11. It has posted earnings per share of -$1.65 in the same period. It has Quick Ratio of 9.94 while making debt-to-equity ratio of 1.63. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRVI, volatility over the week remained 10.10% while standing at 9.69% over the month.
Stock’s fiscal year EPS is expected to rise by 36.09% while it is estimated to increase by 98.19% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on February 26, 2025 offering a Neutral rating for the stock and assigned a target price range of between $9 and $3 to it. Stock get a Mkt perform rating from William Blair on November 08, 2024.
